1. Inicio
  2. Publicaciones
  3. Surgical treatment of liver metastasis from pancreatic cancer

Surgical treatment of liver metastasis from pancreatic cancer

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ramia J.M.
  • Blanco-Asensio N.
  • Rubio J.J.
  • López-López V.
  • Robles-Campos R.
  • Blanco-Fernández G.
  • Borráez A.
  • Guerreiro-Camaño A.
  • Asencio-Pascual J.M.
  • Serradilla-Martín M.
  • Rotellar F.
  • Maina C.
  • Abradelo de Usera M.
  • Loinaz C.
  • Fernández C.
  • Botella A.G.
  • Forner E.M.
  • García Plaza G.
  • Pérez Reyes M.
  • Sánchez B.
  • Tejero Pintor J.
  • Pérez Torres J.B.
  • Pozo C.D.D.
  • Aranda F.P.
  • Achalandabaso Boira M.
  • Rosat Rodrigo A.

Grupos

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality, projected to become the second by 2030. Liver metastases from PDAC (LMPC) are typically deemed inoperable, with dismal prognosis and limited surgical roles. However, emerging evidence suggests that liver resection may benefit selected patients. This study evaluates overall survival (OS), disease-free survival (DFS), and prognostic factors following hepatic resection for synchronous and metachronous LMPC. A retrospective, multicenter cohort study from the REMENOCOR Project included 66 patients who underwent liver resection for LMPC in Spain between 2010 and 2022. Eligible patients were =18 years with histologically confirmed PDAC and liver metastases. Survival outcomes, postoperative morbidity (Clavien-Dindo, CCI), and prognostic indicators were analyzed using Kaplan-Meier and univariate and multivariate methods. R0 resection was achieved in 72.7 % of the patients, and major complications occurred in 19.6 %, with 1.5 % mortality. The 5-year OS and DFS were 26.6 % and 12.7 %, respectively. LMPC were metachronic in 65.2 % of patients. Synchronous resection correlated with significantly poorer OS (5 % vs. 38 %, p < 0.05). Synchronous surgery and advanced pancreatic T-stage emerged as independent negative prognostic factors. Liver resection for metachronous LMPC may offer meaningful survival in selected patients, underscoring the importance of individualized surgical strategies and the need for prospective trials. © 2025 Elsevier Ltd.

Datos de la publicación

ISSN/ISSNe:
0960-7404, 1879-3320

SURGICAL ONCOLOGY-OXFORD  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
-
PubMed:
41110268
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,635 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adult; Aged; Carcinoma, Pancreatic Ductal; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; antineoplastic agent; adult; Article; atelectasis; bile leakage; blood transfusion; cancer chemotherapy; cancer palliative therapy; cancer prognosis; cancer radiotherapy; cancer staging; cancer survival; Charlson Comorbidity Index; cholangitis; cholecystectomy; cohort analysis; disease free survival; ECOG Performance Status; endoscopic retrograde cholangiopancreatography; female; fever; hepatectomy; histology; hospital readmission; human; human tissue; hypovolemic shock; length of stay; liver failure; liver metastasis; lymph node; lymph vessel metastasis; major clinical study; male; microwave thermotherapy; morbidity; multicenter study; neoadjuvant chemotherapy; observational study; open surgery; operation duration; overall survival; pancreatic ductal carcinoma; perineural invasion; postoper

Cita

Compartir